

# Carcinoma of unknown primary (CUP): The role of tumor genomic profiling

Cathleen Park,<sup>1</sup> Daphne Georlette,<sup>2</sup> W. Michael Korn,<sup>3</sup> Joanne Xiu,<sup>4</sup> Hani Babiker,<sup>5</sup> Pedro Barata,<sup>6</sup> Davendra Sohal<sup>7</sup>

<sup>1</sup>Department of Oncology, University of Cincinnati, Cincinnati, Ohio; <sup>2</sup>Department of Clinical and Translational Research, Caris Life Sciences, Phoenix, Arizona; <sup>3</sup>Department of Clinical and Translational Research, Caris Life Sciences, Phoenix, Arizona and Department of Oncology, University California San Francisco, San Francisco, California; <sup>4</sup>Department of Clinical and Translational Research, Caris Life Sciences, Phoenix, Arizona; <sup>5</sup>Department of Oncology, University of Arizona, Tucson, Arizona; <sup>6</sup>Department of Oncology, Tulane University, New Orleans, Louisiana; <sup>7</sup>Department of Oncology, University of Cincinnati, Cincinnati, Ohio

## Background

- CUP is a heterogenous group of cancers characterized by early metastatic dissemination from an unknown site of origin.<sup>1</sup>
- Overall survival is a dismal 6-12 months and untreated CUP is associated with a 4 week life expectancy.<sup>2,3</sup>
- A 2014 review of the molecular profile of 1806 cases of CUP within the Caris Life Sciences database identified biomarkers with potential therapeutic benefits in over 96% of cases<sup>4</sup>
- CUP continues to be a diagnostic and treatment challenge and comprehensive genomic profiling may provide therapeutic insight.

## Study Methods


- Molecular profiles of tumors noted as 'unknown' for tumor primary site within the CARIS Life Sciences database were analyzed utilizing CODEai, a platform that integrates real-world clinical information obtained from insurance claims and medical records with genomic data.
- This real-world cohort consisted of 3,841 tumors
  - 2,137: Adenocarcinoma (ADC)
  - 385: Squamous cell carcinoma (SQ)
  - 1,319: Carcinoma not otherwise specified (NOS).
- CUP-ALL: CUP-ADC + CUP-SQ + CUP-NOS
- Overall survival (OS) was calculated from time of tissue collection to last contact assessed by Kaplan-Meier estimates.



## Results


**Figure 1.**

Within CUP-ALL, the targeted therapy cohort had a longer mOS of 638 days compared to 374 days in the chemotherapy cohort




**Figure 2.**

Within CUP-ALL, the immunotherapy cohort had a longer mOS of 601 days compared to the chemotherapy cohort with a mOS of 372 days




**Figure 3.**

In CUP-ADC, tumors with KRAS wild type had a longer mOS of 397 days compared to 202 days in tumors with a KRAS mutant variant



**Figure 4.**

In CUP-SQ, tumors positive for PD-L1 had a longer mOS of 769 days compared to 508 days in tumors negative for PD-L1



## Conclusion

- The findings from this large real-world cohort demonstrate that key molecular alterations have prognostic and predictive roles in CUP.
- To maximize clinical benefit, prospective studies with various therapeutic classes of cancer treatments exploiting these differences are warranted.

## References

1. Varadhachary GR, Lenzi R, Raber MN, Abbruzzese JL. Carcinoma of Unknown Primary. In: *Abeloff's Clinical Oncology: Fifth Edition*. ; 2014. doi:10.1016/B978-1-4557-2865-7.00094-1
2. Massard C, Voigt JJ, Laplanche A, et al. Carcinoma of an unknown primary: Are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy? *Br J Cancer*. Published online 2007. doi:10.1038/sj.bjc.6603942
3. Conway AM, Mitchell C, Kilgour E, Brady G, Dive C, Cook N. Molecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the 'U' out of 'CUP'. *Br J Cancer*. Published online 2019. doi:10.1038/s41416-018-0332-2
4. Gatalica Z, Millis SZ, Vranic S, et al. Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: Analysis of 1806 cases. *Oncotarget*. Published online 2014. doi:10.18632/oncotarget.2574